中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
2期
201-203
,共3页
前列腺增生%前列舒通胶囊%大鼠
前列腺增生%前列舒通膠囊%大鼠
전렬선증생%전렬서통효낭%대서
Benign prostatic hyperplasia%Qianlieshutong capsule%Rats
目的 探讨前列舒通胶囊治疗前列腺增生症大鼠的效果,并探讨其作用机制.方法 健康雄性SPF级SD大鼠共60只,采用大鼠去势后注射丙酸睾酮致前列腺增生法造模.完全随机分为3组,各20只,即正常对照组(未造模、造模、蒸馏水5 mg/kg)、未治疗组(造模、淀粉胶囊0.25 g/kg以蒸馏水lml配制成悬液灌胃)、前列舒通组(造模、前列舒通胶囊0.25 g/kg以蒸馏水lml配制成悬液灌胃),给药6周后处死,摘取大鼠前列腺并用电光分析天平称重获取前列腺指数,同时取前列腺组织行免疫组化染色,测定表皮生长因子(EGF).结果 前列舒通组大鼠膀胱压力[(6.0±1.3) cm H2O(1 cm H2O =0.098 kPa)]、膀胱最大容积[(2.13 ±0.25)ml]、残余尿量[(44±5)μl]、前列腺指数[(2.00±0.30) mg/g]与未治疗组[分别为(5.4±1.7)cm H2O,(1.51±0.55) ml、(52±5)μl、(2.75±0.16) mg/g]相比差异均有统计学意义(均P＜0.05).免疫组化染色结果显示,前列舒通组EGF表达率为(42.6±7.8)％,明显低于未治疗组[(75.2±8.8)％],且差异有统计学意义(P＜0.05).结论 前列舒通可降低大鼠前列腺体积,其作用机制可能与前列舒通抑制前列腺组织中释放表皮生长因子有关.
目的 探討前列舒通膠囊治療前列腺增生癥大鼠的效果,併探討其作用機製.方法 健康雄性SPF級SD大鼠共60隻,採用大鼠去勢後註射丙痠睪酮緻前列腺增生法造模.完全隨機分為3組,各20隻,即正常對照組(未造模、造模、蒸餾水5 mg/kg)、未治療組(造模、澱粉膠囊0.25 g/kg以蒸餾水lml配製成懸液灌胃)、前列舒通組(造模、前列舒通膠囊0.25 g/kg以蒸餾水lml配製成懸液灌胃),給藥6週後處死,摘取大鼠前列腺併用電光分析天平稱重穫取前列腺指數,同時取前列腺組織行免疫組化染色,測定錶皮生長因子(EGF).結果 前列舒通組大鼠膀胱壓力[(6.0±1.3) cm H2O(1 cm H2O =0.098 kPa)]、膀胱最大容積[(2.13 ±0.25)ml]、殘餘尿量[(44±5)μl]、前列腺指數[(2.00±0.30) mg/g]與未治療組[分彆為(5.4±1.7)cm H2O,(1.51±0.55) ml、(52±5)μl、(2.75±0.16) mg/g]相比差異均有統計學意義(均P＜0.05).免疫組化染色結果顯示,前列舒通組EGF錶達率為(42.6±7.8)％,明顯低于未治療組[(75.2±8.8)％],且差異有統計學意義(P＜0.05).結論 前列舒通可降低大鼠前列腺體積,其作用機製可能與前列舒通抑製前列腺組織中釋放錶皮生長因子有關.
목적 탐토전렬서통효낭치료전렬선증생증대서적효과,병탐토기작용궤제.방법 건강웅성SPF급SD대서공60지,채용대서거세후주사병산고동치전렬선증생법조모.완전수궤분위3조,각20지,즉정상대조조(미조모、조모、증류수5 mg/kg)、미치료조(조모、정분효낭0.25 g/kg이증류수lml배제성현액관위)、전렬서통조(조모、전렬서통효낭0.25 g/kg이증류수lml배제성현액관위),급약6주후처사,적취대서전렬선병용전광분석천평칭중획취전렬선지수,동시취전렬선조직행면역조화염색,측정표피생장인자(EGF).결과 전렬서통조대서방광압력[(6.0±1.3) cm H2O(1 cm H2O =0.098 kPa)]、방광최대용적[(2.13 ±0.25)ml]、잔여뇨량[(44±5)μl]、전렬선지수[(2.00±0.30) mg/g]여미치료조[분별위(5.4±1.7)cm H2O,(1.51±0.55) ml、(52±5)μl、(2.75±0.16) mg/g]상비차이균유통계학의의(균P＜0.05).면역조화염색결과현시,전렬서통조EGF표체솔위(42.6±7.8)％,명현저우미치료조[(75.2±8.8)％],차차이유통계학의의(P＜0.05).결론 전렬서통가강저대서전렬선체적,기작용궤제가능여전렬서통억제전렬선조직중석방표피생장인자유관.
Objective To observe the clinical effect of benign prostatic hyperplasia with Qianlieshutong treatment.Methods Rat model of benign prostatic hyperplasia was established by castration followed by injection of testosterone.The rats were randomly divided into 3 groups:the normal group (without building model,distilled water 5 mg/kg),the notreatment group(building model,starch capsules 0.25 g/kg),and Qianlieshutong group (building model,Qianlieshutong capsule 0.25 mg/kg).The rats were sacrificed.The prostates were sampled and weighed and the prostate index was calculated.Immunohistochemical specimens were prepared and epidermal grouth factor (EGF) were investigated.Results Bladder pressure [(6.0 ± 1.3) cm H2O (1 cm H2O =0.098 kPa],maximum bladder capacity [(2.13 ± 0.25) ml],residual urine volume [(44 ± 5) μl],and prostatic index [(2.00 ±0.30)mg/g] in Qinalieshutong group were significantly lower than those in notreatment group.From immunohistochemical specimens of EGF,EGF levels in Qinalieshutong group was (42.6 ± 7.8) ％,which significantly lower than those in notreatment group.Conclusions Qianlieshutong can decrease prostate weight of rats.Its mechanism may be related to the inhibition of prostate tissue releasing EGF.
